Skip to content

Welcome to Discover Pharma! Today is : October 21, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Reproductive Health

  • Clinical & Regulatory,Medical devices,Pharmaceuticals and therapeutics,Research & Development

    Seegene data finds STI pathogens in 82% of HPV-positive test results

    Seegene analysis of about 60,000 test results found STI pathogens [...]

    July 28, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Gesynta reaches halfway point in Phase 2 endometriosis trial

    Gesynta Pharma has randomised half of the planned patients in [...]

    June 18, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Therapeutic Areas

    Non-hormonal endometriosis drug backed by new investors in Gesynta Pharma round

    Gesynta Pharma has announced the second closing of its Series [...]

    May 5, 2026
  • Opinion & Events

    Oxolife CEO wins EU Women Innovators Prize for work in fertility biotech

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Olink assay correlates with ELISA for measuring endothelin-1
    Categories: Clinical & Regulatory, Research & Development
  • BridgeBio gets FDA Priority Review for oral infigratinib in achondroplasia
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • ViiV’s Cabenuva achieves superior viral suppression in CROWN Phase 3b study
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top